Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 17, 2019 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress

NEW YORK, June 17, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
June 13, 2019 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Three ELZONRIS (tagraxofusp) Clinical Presentations at EHA Congress June 13-15

NEW YORK, June 13, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
June 03, 2019 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces ASCO Presentation of ELZONRIS Phase 2 Clinical Data in CMML and MF; Provides Next Steps for CMML Program

NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
May 20, 2019 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at Upcoming EHA Annual Congress

NEW YORK, May 20, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology...
May 16, 2019 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at the Upcoming ASCO Annual Meeting

NEW YORK, May 16, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology...
May 10, 2019 06:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports First Quarter 2019 Financial Results

Net revenue for ELZONRIS was $5.05 million for the first quarterConference call and live webcast scheduled for today at 8:00 AM ET NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics,...
May 08, 2019 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Host Conference Call on First Quarter 2019 Financial Results on May 10, 2019

NEW YORK, May 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology...
April 25, 2019 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces New England Journal of Medicine Publication of ELZONRIS (tagraxofusp) Pivotal Study Results

NEW YORK, April 25, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
March 18, 2019 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Participate in Panel on Myeloid Tumors at the 31st Annual ROTH Conference

NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
March 15, 2019 16:01 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports Fourth Quarter 2018 Financial Results

NEW YORK, March 15, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right